Brief: Epigenomics Q1 net loss widens to EUR 4.3 million
23/05/2016 07:00
May 23 (Reuters) - Epigenomics AG ECXn.DE :
* Announces 2016 first quarter financial results and reports on operational highlights
* Q1 product revenue increased by 10 percent to 186,000 euros ($208,766.40) (Q1 2015:
169,000 euros)
* Q1 total revenue decreased to 295,000 euros (Q1 2015: 367,000 euros)
* Net loss for Q1 2016 amounted to 4.3 million euros (Q1 2015: net loss 3.2 million euros)
* Outlook 2016 fully confirmed
Source text for Eikon: ID:nEQ1cXPrRa
Further company coverage: ECXn.DE
($1 = 0.8909 euros)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns